|Bid||1.0900 x 900|
|Ask||1.1100 x 1000|
|Day's range||1.0400 - 1.1100|
|52-week range||0.9620 - 5.8000|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.